MiNK Therapeutics, Inc. (INKT)
(Delayed Data from NSDQ)
$15.09 USD
-0.26 (-1.69%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $15.08 -0.01 (-0.07%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth F Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
INKT 15.09 -0.26(-1.69%)
Will INKT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for INKT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INKT
New Strong Sell Stocks for August 22nd
INKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for INKT
Is INKT poised for gains? 20 Day Moving Average Support shows up after sliding 1.69%
Crossed Above 20 Day Moving Average appears for INKT after 7.79% move
Is INKT showing downside potential? 20 Day Moving Average Resistance shows up after sliding 2.4%
MiNK Therapeutics appoints Hammond as Head of Inflammatory, Pulmonary Diseases
MiNK Therapeutics appoints Hammond as Head of Inflammatory, Pulmonary Diseases